Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
Go back to Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 8.07 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.07 | 52 Week High | $9.23 | |||
| Open | $8.07 | 52 Week Low | $1.16 | |||
| Day High | $8.07 | P/E | N/A | |||
| Day Low | $8.07 | EPS | $-0.30 | |||
| Volume | 1,461 | |||||
